 |
Conceptus(R) to Hold Fourth Quarter Financial Results Conference Call on February 23, 2012
Jan 31, 2012
|
20.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the leading non-surgical permanent birth control method, today announced that the Company will release 2011 fourth quarter financial results and introduce 2012 full year financial guidance on Thursday, February 23, 2012, ...
|
|
Conceptus(R) Announces That Hologic's Motion for New Trial in Patent Infringement Case is Denied
Jan 9, 2012
|
19.7 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS),developer of the Essure® procedure, the leading non-surgical permanent birth control method, announced today that Judge William Alsup of the United States District Court, Northern District of California, denied Hologic Inc.'s motions seeking to overturn the j...
|
|
Conceptus(R) to Discontinue GYNECARE THERMACHOICE(R) Promotion and Restructure U.S. Sales Organization
Jan 9, 2012
|
19.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the leading non-surgical permanent birth control method, announced today the Company's decision to discontinue its promotion of the GYNECARE THERMACHOICE® Uterine Balloon Therapy System to U.S. OB/GYN physician office...
|
|
Conceptus(R) Announces Private Exchange of Convertible Senior Notes Due 2027 for Convertible Senior Notes Due 2031
Dec 20, 2011
|
16.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), announced today that the Company has entered into separate, privately-negotiated exchange agreements with certain holders of the Company's outstanding 2.25% Convertible Senior Notes due 2027 ("Existing Notes") to exchange $50.04 million of its $86.25 million agg...
|
|
Conceptus(R) Appoints D. Keith Grossman President and Chief Executive Officer
Dec 8, 2011
|
22.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 8, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the leading non-surgical permanent birth control method, announced today that D. Keith Grossman, 51, has been appointed President and Chief Executive Officer, effective immediately. Mr. Grossman succeeds Mark M. Sieczkarek...
|
|
Conceptus(R) Updates 2011 Financial Guidance
Dec 8, 2011
|
20.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 8, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the leading non-surgical permanent birth control method, today announced updated financial guidance for 2011.
The Company expects 2011 net sales to be in the range of $126 million to $128 million, compared with pre...
|
|
Conceptus(R) to Present at the 23rd Annual Piper Jaffray Health Care Conference
Nov 21, 2011
|
17.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, announced today that management is planning to present at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29, 2011 at 11:...
|
|
Conceptus(R) Receives FDA Approvable Letter for Compatible Use of Hologic's NovaSure(R) With Essure(R) Inserts in Place
Nov 8, 2011
|
19.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, announced today that it has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for labeling changes pertaining to the us...
|
|
Conceptus(R) Announces 10-Year Commercial Data for Essure(R) at 40th AAGL Global Congress of Minimally Invasive Gynecology
Nov 8, 2011
|
22.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available*, today released a new data report on Essure's 10-year commercial success at the 40th AAGL Global Congress of Minimally Invasive Gynecology in Hollyw...
|
|
Conceptus(R) to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Nov 7, 2011
|
19.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 7, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, announced today that management is planning to present at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15, 2011 ...
|
|
Conceptus(R) Reports Third Quarter Financial Results
Oct 25, 2011
|
40.3 KB |
|
| |
Domestic physician penetration metrics solid
Updates 2011 financial guidance
MOUNTAIN VIEW, Calif., Oct. 25, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS),developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today reported financial results for the three mo...
|
|
Conceptus(R) Wins Favorable Verdict in Patent Litigation Against Hologic; Jury Awards Conceptus $18.8 Million
Oct 17, 2011
|
21.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct. 17, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today announced that it has won a favorable jury verdict in its patent infringement lawsuit against Hologic, Inc. (Nasdaq:HOLX) in the United State...
|
|
Conceptus(R) Acquires All Distribution Rights Related to the Essure(R) Procedure in the Netherlands
Oct 4, 2011
|
20.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct. 4, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today announced that it has acquired from its Dutch distributor certain assets and all distribution rights of the Essure device for approximately $3...
|
|
Conceptus(R) to Hold Third Quarter Financial Results Conference Call on October 25, 2011
Oct 4, 2011
|
19.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct. 4, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today announced that the Company will release 2011 third quarter financial results on Tuesday, October 25, 2011, after the close of market. Manageme...
|
|
Conceptus® Celebrates 10 Years of the Essure® Procedure With Symposium at European Society for Gynaecological Endoscopy (ESGE) 20th Annual Congress
Sep 20, 2011
|
15.4 KB |
|
| |
Versailles, France, September 20, 2011 - Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, will host a symposium to celebrate the 10-year anniversary since the Essure procedure received the CE mark of approval for use in Europe. The symp...
|
|
Conceptus(R) Enters Into New Revolving Line of Credit Agreement With Wells Fargo Bank, N.A.
Aug 26, 2011
|
21.0 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug. 26, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today announced that it has entered into a new revolving line of credit arrangement with Wells Fargo Bank, N.A., providing the Company a working ca...
|
|
Conceptus(R) to Present at the Stifel Nicolaus 2011 Healthcare Conference
Aug 24, 2011
|
19.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug. 24, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, announced today that management is planning to present at the Stifel Nicolaus 2011 Healthcare Conference on Thursday, September 8, 2011 at 10:55 a....
|
|
Conceptus(R) Announces FDA Approval to Remove Nickel Contraindication From the Essure Procedure Instructions
Aug 4, 2011
|
22.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS),developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today announced that effective immediately, the U.S. Food and Drug Administration (FDA) has approved the removal of the nickel hypersensitivity contr...
|
|
Conceptus(R) Reports Second Quarter Financial Results
Aug 4, 2011
|
38.9 KB |
|
| |
Reports Net Sales of $33.8 Million, 27% Sequential Growth
Expands Hysteroscopic Sterilization Market With Strong New-Physician Penetration Metrics
Updates Financial Guidance
MOUNTAIN VIEW, Calif., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the ...
|
|
Conceptus(R) Applauds Mandate to Cover Permanent Birth Control Under the Patient Protection and Affordable Care Act of 2010
Aug 1, 2011
|
22.7 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug. 1, 2011 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today applauded the decision by the U.S. Department of Health and Human Services (HHS) to mandate that permanent birth control be a covered procedur...
|
|
|
